Decree No. 27 / 2022 Coll.
Decree amending Decree No. 228 / 2008 Coll., on the Registration of Medicinal Products, as amended
Valid
Order
Effective from 08.03.2022
Text versions:
08.03.2022
21.02.2022
Zobrazeno prvních 200 z celkem 241 ustanovení tohoto předpisu.
Zobrazit celý předpis →
Pro stažení celého znění použijte tlačítko Stáhnout výše.
27
DECLARATION
of 3 February 2022
amending Decree No. 228 / 2008 Coll., on the Registration of Medicinal Products, as amended
Article 3 (3) (a), § 3 (3) (a), § 3 (a), § 3 (a), § 3 (a), § 4 (b), § 4 (b), § 4 (b), § 5 (c), § 5 (b), § 3 (a), § 3 (a), § 3 (b), § 3 (a), § 3 (b), § 3 (a), § 3 (a), § 3 (a), § 3 (a), § 3 (a), § 3 (b), § 3 (b), § 3), § 3 (b), § 3 (a), § 3 (a), § 3), § 3 (a), § 3), § 3 (a), § 3 (a), (a), (b), (b), (a), (b), (b), (b), (b), (b), (b), (b), (b), (b), (b), (b), (b), (b), (b
Decree No. 228 / 2008 Coll., on the Registration of Medicinal Products, as amended by Decree No. 13 / 2010 Coll., Decree No. 171 / 2010 Coll., Decree No. 255 / 2013 Coll. and Decree No. 205 / 2018 Coll., is amended as follows:
1. footnote 5 shall read:
"5) § 132 and 136 of Act No. 89 / 2012 Coll., Civil Code. '.
2. in Article 2 (1), point (m) shall be deleted;
Point (n) shall be renumbered as point (m).
3. In Article 2 (2), the words "taking into account the need for urgent initiation of the treatment programme 'and the words" if the medicinal product is subject to registration' are deleted.
4. In Article 2 (3) (c), the words "the workplace at which the treatment programme takes place" shall be inserted after the words "the programme."
5. in Article 3 (6) (a) (6), the words "and, in the form of a barcode, the European Code of Conduct (hereinafter referred to as" the European Code "), if it is a human product; in the case of veterinary products, the European code may be indicated on the packaging 'deleted.
6. In Article 3 (6) (b) (2), the words "in sufficient quantities for patients in the Czech Republic or for the provision of veterinary care 'shall be inserted after the word" market'.
7. In Article 3 (6) (b) (6), "the marketing authorisation holder 'is replaced by" the package size'.
8. in § 3 (6) (b) (7):
"7. the marketing authorisation holder shall ensure that each individual package leaflet is accompanied by an approved package leaflet in the Czech language or, in exceptional cases, if the medicinal product is for human use, the marketing authorisation holder shall otherwise ensure that the patient receives the information contained in the relevant package leaflet."
9. in Article 6 (1) (a), the words "except medicinal teas and medicinal teas containing a strong or very strong active substance" shall be deleted;
10. in Article 6 (1), point (b) is deleted;
Points (c) to (i) shall be renumbered (b) to (h).
11. in Article 6 (1), point (g) is deleted;
Point (h) shall be renumbered as point (g).
12. in Article 6, at the end of paragraph 1, the dot is replaced by a comma and the following point (h) is added:
"(h) human products containing exclusively the active substance or active substances of the pharmacotherapy group antacid."
13. in Article 9 (1), point (d) is deleted;
Points (e) and (f) shall be renumbered as points (d) and (e).
14. in Paragraph 9 (1), the comma at the end of point (d) shall be replaced by a dot and point (e) shall be deleted;
15. in Article 11 (c), the words "and summaries of product characteristics approved by foreign control authorities" shall be deleted and the words "point (f)" shall be replaced by "point (e)."
16. in Article 11, point (e) is deleted;
Points (f) to (k) shall be renumbered as points (e) to (j).
17. in Article 11 (e), the words "summary of the pharmacovigilance system," deleted, the word "non-clinical" shall be replaced by "pre-clinical" and the words "if the medicinal product does not have a risk management plan," shall be added; in the absence of a medicinal product, the holder of the marketing authorisation shall provide a justification for not being submitted. "
18. in Paragraph 11 (f) (1), "preclinical" is replaced by "preclinical."
19. in Article 13 (1) (e), the word "significant" shall be inserted after the word "health."
20. In Article 13 (3), the words "in the form of a barcode, the European code is different from that of the reference product if it is for human products' are deleted.
21. in Article 15 (1) (a), the words "or age group" shall be inserted after the word "age."
22. Paragraph 15 (2) is deleted.
Paragraphs 3 to 6 shall become paragraphs 2 to 5.
23. in Article 15, paragraphs 3 and 4 are deleted;
Paragraph 5 shall become paragraph 3.
24. in Article 16 (g):
"(g) periodic safety update reports shall be stored and archived in the Agency set up a repository of periodic safety update reports on medicinal products and corresponding assessment reports,";
25. in Article 16 (h), the words "paper or paper" shall be deleted;
26. in Paragraph 18 (2) (e):
"(e) the number of prescribed or used packages of unregistered medicinal product for human use, indicating the number of patients;"
27. in Paragraph 18 (2), the comma at the end of point (f) shall be replaced by a dot and points (g) and (h) shall be deleted;
28. In Annex 1, in the introductory part, the word "non-clinical 'is replaced by" preclinical' and the word "non-clinical 'is replaced by" preclinical'.
29. In Annex 1, Part I, point 1.3, the title reads as follows:
"Summary of Product Characteristics as set out in Annex No 3, labelling as set out in Annex No 5, package leaflet as set out in Annex No 4 and models of outer and inner packaging including colour graphic presentation '.
30. In Annex 1, Part I, point 1.4, the word "non-clinical 'is replaced by the word" preclinical' and the word "non-clinical 'is replaced by" preclinical'.
31. In Annex 1, Part In point 2, "non-clinical 'is replaced by" preclinical' and "non-clinical 'is replaced by" preclinical'.
32. In Annex 1, Part In point 2.4, in the title, the word "non-clinical 'is replaced by" preclinical'.
33. In Annex 1, Part I, point 2.4, the word "non-clinical 'is replaced by" pre-clinical', the word "non-clinical 'is replaced by the word" pre-clinical', and the word "non-clinical 'is replaced by" pre-clinical'.
34. In Annex 1, Part In the title, point 2.6, the word "non-clinical 'is replaced by" preclinical'.
35. In Annex 1, Part I, point 3.2 (12):
"(12) In the case of a product referred to in the second subparagraph of Article 1 (8) or the second subparagraph of Article 1 (9) of Regulation (EU) 2017 / 745 of the European Parliament and of the Council (hereinafter referred to as" Regulation 2017 / 745 '), the product shall include, where available, the results of the conformity assessment of the part which constitutes a medical device with the relevant general safety and efficacy requirements set out in Annex I to Regulation (EU) 2017 / 745, the declaration of conformity issued by the manufacturer or the relevant certificate issued by the notified body allowing the manufacturer to place the CE marking on the medical device. Where the documentation does not include such conformity assessment results and where the involvement of a notified body is required for conformity assessment of a device in its separate use in accordance with Regulation 2017 / 745, the applicant's Institute shall request the applicant to provide an opinion on the conformity of the part of the medical device with the relevant general safety and efficacy requirements set out in Annex I to Regulation 2017 / 745 issued by the notified body designated in accordance with Regulation 2017 / 745 for the relevant type of device.';
36. In Annex 1, Part I, point 3.2.2.2, the word "non-clinical 'is replaced by" preclinical'.
37. in Annex 1, Part I, point 3.2.2.4 (d), the word "non-clinical" is replaced by "preclinical."
38. In Annex 1, Part In point 4, in the title, the word "NON-KLINIC 'is replaced by" PREKLINIC'.
39. in Annex 1, Part I, point 4.1.2.2 (f), the word "non-clinical" is replaced by the word "preclinical."
40. In Annex No 1, Part II, point 1, in the introductory part, the word "non-clinical 'is replaced by" preclinical'.
41. In Annex No 1, Part II, point 1 (c) and (d), the word "non-clinical 'is replaced by the word" pre-clinical'.
42. In Annex No 1, Part II, point 2, in the introductory part, "non-clinical 'is replaced by" preclinical'.
43. In Annex No 1, Part II, points 2.5 and 7, the word "non-clinical 'is replaced by" preclinical'.
44. In Annex 1, Part III, point 5, the word "non-clinical 'is replaced by" preclinical'.
45. In Annex 1, Part IV, point 1, the word "non-clinical 'is replaced by" preclinical' and the word "oncogenicity 'is replaced by the word" oncogenicity'.
46. in Annex 1, Part IV, point 3.3.2.3 (e), "non-clinical" is replaced by "pre-clinical."
47. In Annex No 1, Part IV, point 4.1, the word "non-clinical 'is replaced by" pre-clinical' and the word "non-clinical 'is replaced by the word" preclinical'.
48. In Annex 1, Part IV, point 4.2, the word "non-clinical 'is replaced by" preclinical'.
49. In Annex 2, Title I, Part 2, points (b) and (c) are replaced by the following: point 1.2 is replaced by the following:
50. In Annex 2, Title I, Part 3, points (b) and (c) are replaced by the following: B In points 2.1 and 3, the word "Describe 'is replaced by" Describe'.
51. In Annex No 2, Title III, point 1, the word "non-clinical 'is replaced by" preclinical'.
52. In Annex 3, Part In point 2, the words "and their quantitative composition 'shall be inserted after the words" active substances', the words "Latin 'shall be replaced by the words" Czech language', the words "and their quantitative composition 'shall be inserted after the words" the use of the product', the words "these excipients shall be included in the instructions issued by the Commission 'and the words" In case the product contains excipients, reference shall be made to point 6.1 of the SPC.';
53. In Annex 3, Part In point 3, the words "the reasons why it is introduced 'are replaced by the words" its function is specified'.
54. In Annex 3, Part A, point 4.2, the words "liver or kidney failure 'are replaced by the words" liver or kidney disorders'.
55. In Annex 3, Part and point 4.2 is replaced by the following:
"- method of administration."
56. In Annex 3, Part A, point 4.4, the words "renal, hepatic 'are replaced by the words" liver or kidney disorders'.
57. In Annex 3, Part A, point 4.5, "preparations' is replaced by" substances'.
58. In Annex 3, Part A, point 4.7, the words "enter the entry 'are replaced by the words" information'.
59. In Annex 3, Part A, point 4.9, the words "experience of overdose in animals; experience of overdose 'are replaced by the words" signs and symptoms of overdose' and the words "and procedures in emergency cases and possible antidotes' are added at the end of the text.
60. In point 5.1 of Part A of Annex 3, the dot is replaced by a comma at the end of the last indent and the following indents are added:
"- whether it is a similar biological medicinal product,
- whether the product has not been subject to an obligation to submit the results of studies in accordance with the paediatric investigation plan or has been deferred or is a generic for a reference product for which that obligation has not been established or such an obligation has been deferred,
- information on whether the product has been authorised in exceptional circumstances and, therefore, because of the rare nature of the disease for which it is indicated, for scientific or ethical reasons, it has not been possible to obtain complete information on the benefits and risks of the medicinal product, or is a generic for the reference product which has been authorised in exceptional circumstances. "
61. In Annex 3, Part A, point 6.5, the title reads:
"Type of packaging and contents of packaging and, if necessary, special equipment for use, administration or implantation '.
62. In Annex 3, Part A, point 6.6, the title reads:
"Special precautions for disposal and other handling '.
63. In Annex 3, Part In point 6.6, "use 'is replaced by" use';
64. In Annex 3, Part B, point 7, the title reads:
Marketing Authorisation Holder.
65. Part of Annex 4 And including the title reads:
"A. The content and breakdown requirements of the package leaflet of medicinal products for human use are specified in the regularly updated templates on the Agency's website.
In the case of medicinal products listed in Article 23 of Regulation (EC) No 726 / 2004, the following sentence shall be added to the package leaflet: "This medicinal product is subject to further monitoring. 'This sentence shall be preceded by the black symbol referred to in Article 23 of Regulation (EC) No 726 / 2004 and followed by an appropriate standardised explanation.
1. The data provided in the package leaflet must be consistent with the SPC.
2. This leaflet is set out in:
(a) the name of the medicinal product followed by its strength and pharmaceutical form and, where appropriate, the target population; if the product contains up to 3 active substances, the international non-proprietary name (INN) in the Czech language or, in the absence thereof, the common name shall be added; in the case of specific homeopathic products registered under Section 28a of the Drug Act, in addition to the clear mention of the words "homeopathic medicinal product"
in the package leaflet, indicate the name of the preparation, consisting of the scientific name of the basic substance or of the basic substance followed by the degree of dilution, using the pharmacopoeia symbol and the pharmaceutical form to express that degree; where the name of the product is fictional, the scientific name of the basic substance or of the basic substance followed by the degree of dilution shall be added in addition to the pharmaceutical form,
(b) the pharmacotherapy group or mode of action in terms easily understandable to the patient,
(c) therapeutic indications; in the case of specific homeopathic products registered under Section 28a of the Drug Act, the sentence "Homeopathic medicinal product used traditionally in homeopathy for mitigation 'or" Homeopathic medicinal product used traditionally in homeopathy for treatment' shall be given,
(d) contraindications,
(e) special precautions for the safe use of the product,
(f) interactions with other products and other interactions related to the way of life, in particular interactions with food, drinking, alcohol and smoking;
(g) specific conditions of use for certain categories of users or patients, in particular children, pregnant or lactating women, women of childbearing potential, elderly persons, persons with special pathological conditions;
(h) information on the possibility of affecting the ability to drive and use machines,
(i) information on excipients the knowledge of which is important for the safe and effective use of the product and is included in the guidelines issued by the Commission;
(j) dosage, in particular dose size,
(k) the route of administration, if necessary, the route of administration, the frequency of administration, the timing of administration or the duration of treatment, if any, and, where appropriate, the measures to be taken in the event of overdose, the method of action to be taken if one or more doses have not been taken, or the risk of discontinuation of treatment,
(l) express advice that a doctor or pharmacist should be consulted if necessary,
(m) a description of the adverse reactions that may occur with the approved use of the product and, if necessary, the measures to be taken if they occur; a call for patients to notify their doctor or pharmacist of their suspected adverse event, in particular if it is not mentioned in the package leaflet or if it occurs seriously; the standardised text explicitly requesting patients to report such suspicions to healthcare professionals or directly to the Institute,
(n) a warning that the product must be kept out of the sight and reach of children,
(o) a reference to the expiry date indicated on the package and a notice indicating the prohibition of use of the product after the expiry date or, where appropriate, to certain visible signs of reduced quality,
(p) special storage conditions,
(q) notice of the disposal procedure;
(r) the content of all active substances, expressed in qualitative and quantitative terms, expressed in the common name in the Czech language and the content of the excipients in the Czech nomenclature for each product variant; in the case of specific homeopathic products registered under Section 28a of the Drug Act, the qualitative and quantitative content of all active substances, expressed by the scientific name of the basic substance or of the basic substances followed by the degree of dilution, using the pharmacopoeia symbol and the qualitatively expressed content of the excipients in the Czech nomenclature for each variant of the preparation,
(s) the pharmaceutical form and contents of the pack, indicated as weight, volume or number of doses of the product, including any other components of the pack, including spoon, cotton swab, needle, etc.,
(t) the business name and registered office of the marketing authorisation holder, if any, or the name or, where applicable, the name, surname and place of business of the marketing authorisation holder, if any, and the same details of the manufacturer, if the marketing authorisation holder does not agree with the marketing authorisation holder, and, where appropriate, the name of the representative appointed by the marketing authorisation holder;
(u) where the product is registered in accordance with the procedure laid down in Article 41 of the Law on Medicines in the Member States concerned under different names, the list of names registered by each Member State shall be given;
(v) date of the last revision of the package leaflet.
3. In the case of radiopharmaceuticals, radionuclide generators, radiopharmaceuticals or radionuclide precursors, detailed package leaflet shall be attached to the package, the text of which is in accordance with the provisions of point 2. In addition, the information shall include all measures in accordance with other legislation to be taken by the user and the patient during preparation and administration of the product and specific measures for the disposal of the immediate packaging and its unused contents.
4. In the case of homeopathic products authorised under the procedure provided for in Section 28 of the Drug Act, in addition to the clear mention of the words "homeopathic medicinal product without approved indications' in the package leaflet,
(a) the name of the preparation, consisting of the scientific name of the basic substance followed by the degree of dilution, using the pharmacopoeia symbol and the pharmaceutical form to express that degree; where the name of the product is fictional, the scientific name of the basic substance followed by the degree of dilution shall be added in addition to the pharmaceutical form;
(b) contraindications,
(c) special warnings aimed at the safe use of the product;
(d) information on the possibility of affecting the ability to drive and use machines,
(e) information on auxiliary substances the knowledge of which is important for the safe and efficient use of the product and is included in the guidelines issued by the Commission;
(f) the warning "Use according to the advice of a homeopathic expert" or other special warnings if necessary for the product,
(g) the route of administration and, if the route of administration is not obvious, the route of administration,
(h) dosage, in particular dose, if necessary,
(i) explicit advice to consult a doctor or pharmacist where appropriate;
(j) a standardised text explicitly requesting patients to report suspected adverse reactions to health professionals or directly to the Institute;
(k) a warning that the product must be kept out of the sight and reach of children,
(l) a reference to the expiry date indicated on the package and to the notice indicating the prohibition of use of the product after the expiry date or, where appropriate, to certain visible signs of reduced quality,
(m) special storage conditions,
(n) notice of the disposal procedure;
(o) the qualitative and quantitative content of all active substances, expressed by the scientific name of the basic substance or of the basic substances followed by the degree of dilution, using the Pharmacopoeia symbol and the qualitative content of the excipients in the Czech nomenclature for each variant of the preparation,
(p) the pharmaceutical form and contents of the pack, indicated as weight, volume or number of doses of the preparation, including measuring spoon or spoon and other components of the pack,
(q) the business name and registered office of the marketing authorisation holder, if it is a legal person, or the name or, where applicable, the name, surname and place of business of the marketing authorisation holder, if it is a natural person, and the same details of the manufacturer if the marketing authorisation holder does not agree with the marketing authorisation holder and, where appropriate, the name of the representative appointed by the marketing authorisation holder;
(r) where the product is registered in accordance with the procedure laid down in Article 41 of the Law on Medicines in the Member States concerned under different names, the list of names registered by each Member State shall be given;
(s) the date of the last revision of the package leaflet.
5. The package leaflet may include symbols or pictograms designed to explain a certain indication on the package leaflet or on the package leaflet, or any other information useful for the patient. These data are consistent with the SPC and do not contain elements of an advertising nature. '
66. Part of Annex 5 And including the title reads:
"A. The data on the packaging of medicinal products for human use are specified in the regularly updated templates on the Agency's website.
1. On the outer packaging of the preparation, where applicable on the inner packaging, if the outer packaging does not exist, the following shall be indicated:
(a) the name of the medicinal product followed by its strength and pharmaceutical form and, where appropriate, the target population; if the product contains up to 3 active substances, the international non-proprietary name (INN) in the Czech language or, in the absence thereof, the common name shall be added; where the information on the packaging is given in several languages, the international non-proprietary name (INN) may be indicated in English or Latin; in the case of specific homeopathic products registered under Section 28a of the Drug Act, the name of the preparation consisting of the scientific name of the basic substance followed by the degree of dilution, using the pharmaceutical symbol and the pharmaceutical form to express this degree; where the name of the product is fictional, the scientific name of the basic substance or of the basic substance followed by the degree of dilution shall be added in addition to the pharmaceutical form,
(b) a qualitative and quantitatively expressed content of active substances in the unit of the dose or according to the form administered in the volume or weight, using their common names in the Czech language; where the information on the packaging is given in several languages, the common names of the active substances may be indicated in English or Latin; in the case of specific homeopathic preparations registered under Section 28a of the Medicines Act, the scientific name of the basic substance or of the basic substances followed by the degree of dilution, using the pharmacopoeia symbol to express this degree, in the case of specific preparations containing tissues or cells, indicating whether they are of human or animal origin,
(c) a list of the excipients which have a demonstrable effect on the organism and are included in the guidelines issued by the Commission; where parenteral, topical or eye preparations are involved, all excipients shall be reported; the names of the excipients are given in the Czech language,
(d) the pharmaceutical form and contents of the pack, indicated as weight, volume or number of doses of the product, including measuring spoon or spoon and other components of the pack,
(e) method of administration and route of administration; leave a space for the prescribed dose,
(f) a warning that the product must be kept out of the sight and reach of children,
(g) special warnings, if necessary for the product, if it affects human motor skills or risks of health complications;
(h) the expiry date (month, year),
(i) special storage conditions,
(j) specific measures designed to dispose of a unused product or waste material derived from such a preparation, where this is required to limit the adverse effects of its action on the environment, in accordance with other legislation,
(k) the business name and registered office of the marketing authorisation holder, if any, if it is a legal person, or the name or, where appropriate, the name, surname and place of business of the marketing authorisation holder, if any, the natural person and, where appropriate, the name of the representative appointed by him;
(l) the product registration number,
(m) the batch number,
(n) in the case of dispensation without prescription, instructions for use of the product,
(o) an internationally recognised identification standard where the identification of the medicinal product is not ensured by a unique identifier as part of the protection features.
2. The internal packaging shall bear the particulars referred to in point 1; except for:
(a) blisters placed in outer packs marked in accordance with point 1, on which it shall be indicated
(i) the name of the medicinal product followed by its strength and pharmaceutical form and, where appropriate, the target population; if the product contains up to 3 active substances, the international non-proprietary name (INN) in the Czech language or, in the absence thereof, the common name shall be added; where the information on the packaging is given in several languages, the international non-proprietary name (INN) may be indicated in English or Latin; in the case of specific homeopathic preparations registered under § 28a of the Drug Act, the name of the preparation consisting of the scientific name of the basic substance followed by the degree of dilution, using the Pharmacopoeia symbol and the pharmaceutical form to express this degree; where the name of the product is fictional, the scientific name of the basic substance or of the basic substance followed by the degree of dilution shall be added in addition to the pharmaceutical form,
(ii) the business name or name of the marketing authorisation holder;
(iii) the expiry date,
(iv) the lot number,
(v) other relevant information if necessary;
(b) small inner packaging which does not allow for the legible location of all the data required under point 1 on which it is indicated
(i) the name of the preparation followed by its strength and pharmaceutical form; where the product contains up to 3 active substances, the international non-proprietary name (INN) in the Czech language or, if it does not exist, the common name, if the information on the packaging is given in several languages, may be indicated in the English language or Latin; the route of administration,
(ii) method of administration,
(iii) the expiry date,
(iv) the lot number,
(v) the contents of the pack, indicated as weight, volume or number of doses of the product,
(vi) other relevant information if necessary.
3. In addition, in the case of products containing radionuclides, the outer packaging and the inner packaging shall be indicated as a symbol of radioactivity. The marking on the shielding shall contain the particulars referred to in point 1. In addition, the label on the shielding package contains a full explanation of the encoding used on the vial and shall be provided, where necessary, at the given time and date of activity per dose or bottle and number of capsules or for liquids the number of millilitres in the container. The vial should be labelled with this information
(a) name or product code including name or chemical mark of radionuclide,
(b) identification of the lot and the period of application;
(c) the international symbol for radioactivity;
(d) the name and address of the marketing authorisation holder,
(e) the amount of activity, where necessary, at the given time and date of activity per dose or vial and the number of capsules or for liquids the number of millilitres in the inner packaging.
4. In the case of homeopathic products authorised under the procedure provided for in Section 28 of the Drug Act, in addition to the clear mention of the words "homeopathic medicinal product without approved indications', only the following information shall appear on the label:
(a) the name of the preparation consisting of the scientific name of the basic substance followed by the degree of dilution and the pharmaceutical form; where the name of the product is fictional, the scientific name of the basic substance followed by the degree of dilution shall be added;
(b) the scientific name of the basic substance or substances followed by the degree of dilution;
Sign in for notes, favorites and notifications
Regulation Information
| Citation | Decree No. 27 / 2022 Coll., amending Decree No. 228 / 2008 Coll., on the Marketing Authorisation of Medicinal Products, as amended |
|---|---|
| Regulation Type | Order |
| Author | - |
| Collection | Code of Laws |
| Date of Promulgation | 21.02.2022 |
|---|---|
| Effective from | 08.03.2022 |
| Effective until | - |
| Status | Valid |
Public Contracts 5
DNS - Očkovací látky - Oznámení k aktualizaci elektronického katalogu č. 19
Česká republika - Ministerstvo obrany
Avenier a.s.
1 333 584 CZK
30.09.2025
DNS - Očkovací látky - Oznámení k aktualizaci elektronického katalogu č. 17
Česká republika - Ministerstvo obrany
Avenier a.s.
1 230 376 CZK
04.09.2025
DNS – Očkovací látky- Oznámení č. 10 - JK - Trading spol. s r.o.,
Česká republika - Ministerstvo obrany
JK - Trading spol. s r.o.
130 694 CZK
28.02.2025
DNS – Očkovací látky- Oznámení č. 10 - JK - Trading spol. s r.o.,
Česká republika - Ministerstvo obrany
JK - Trading spol. s r.o.
130 694 CZK
28.02.2025
DNS - Očkovací látky - Oznámení k aktualizaci elektronického katalogu č. 5 - JK - Trading spol. s r....
Česká republika - Ministerstvo obrany
JK - Trading spol. s r.o.
633 800 CZK
30.08.2024
Source:
Hlídač státu
(CC BY 3.0 CZ)
The regulation text is for informational purposes only.
Comments 0